GlassScriptPhysician profile
Sumant Ponnala
NPI 1568877934
$672.33
in general payments reported to CMS, 2019-2025
15 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $440 · 2020: $106 · 2021: $126.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $235.11 | 2019-2021 | |
| Amgen INC. | $80.54 | 2019-2021 | |
| Abbvie INC. | $54.72 | 2019-2020 | |
| Novo Nordisk INC | $51.62 | 2019-2021 | |
| Esperion Therapeutics, INC. | $38.67 | 2021 | |
| Pfizer INC. | $37.13 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $26.31 | 2019 | |
| Astellas Pharma US INC | $26.26 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $25.44 | 2019-2021 | |
| Lilly USA, LLC | $24.55 | 2019 | |
| Radius Health, INC. | $18.05 | 2020 | |
| Allergan, INC. | $17.72 | 2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $13.74 | 2019 | |
| Merck Sharp & Dohme LLC | $11.35 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $11.12 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sumant Ponnala listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.